← FDA DRUG APPROVALS

FDA ANDA · ANDA206736

RIFAMPIN

Sponsor: WATSON PHARMS TEVA

APPLICATION
ANDA206736
TYPE
ANDA
ORIGINAL APPROVAL
2016-01-19
LATEST ACTION
2020-07-06
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

RIFAMPINDiscontinued
RIFAMPIN 600MG/VIAL · INJECTABLE · INJECTION

Approval history

2020-07-06Labeling · Supplement 1 · standardAP
2020-07-06Labeling · Supplement 2 · standardAP
2020-07-06Labeling · Supplement 3 · standardAP
2016-01-19UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →